Elicio Therapeutics, Inc. (ELTX) stock
ELTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.50−0.09 (-5.66%)
Close on Nov 19, 2026Market cap $39.42MP/E –Yield –
Elicio Therapeutics gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Elicio Therapeutics's gross profit for the twelve months ending Dec 31, 2021 was $27.88M, up 1549.6% year over year. For fiscal 2022 it was $2.30M, down 91.7% from the year before.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $2.30M | -91.7% |
| FY2021 | Dec 31, 2021 | $27.88M | +1549.6% |
| FY2020 | Dec 31, 2020 | $1.69M | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2021 | Dec 31, 2021 | $25.51M | +7560.1% |
| Q3 FY2021 | Sep 30, 2021 | $1.46M | +204.8% |
| Q2 FY2021 | Jun 30, 2021 | $540.00K | +36.4% |
| Q1 FY2021 | Mar 31, 2021 | $371.00K | -23.0% |
| Q4 FY2020 | Dec 31, 2020 | $333.00K | – |
| Q3 FY2020 | Sep 30, 2020 | $479.00K | – |
| Q2 FY2020 | Jun 30, 2020 | $396.00K | – |
| Q1 FY2020 | Mar 31, 2020 | $482.00K | – |
See a number that looks wrong?